Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV Infections: early-phase trial registry
56 of 615 indexed HIV Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7 of 28,707 conditions by registered trial count.
615 US clinical trials · 56 currently recruiting · #7 of 28,707 conditions by registered trial count
HIV Infections: 615 US clinical trials tracked, 56 recruiting.
HIV Infections is the subject of 615 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 92 are in Phase 3-4 (later-stage) and 266 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 195 of these trials.
Enrollment posture brief
Registry condition hiv-infections
OPEN 56 | RECR 9% | LATE 92 | EARLY 266 | RANK #7 | SPON 195
Volume-matched condition peers
Nearest open-share peer: Acute Lung Injury (9% recruiting · 11 trials)
HIV Infections lists 56 open slots (9% of 615 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV Infections is recruiting below its size-band peers.
56 of 615 indexed trials (9.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV Infections research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 195 of 615 trials (31.7%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV Infections enrolment sits around 100 participants.
Median target enrolment is 100 among the 543 trials that report a genuine target (sentinel values excluded). 267 of those (49.2%) plan for fewer than 100 participants.
-
HIV Infections research is mostly interventional.
549 interventional and 66 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
615 total, page 10 of 13
Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00393276
Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects
Johns Hopkins University
NCT00344123
A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea
Unimed Pharmaceuticals
NCT00002444
Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study
Indiana University
NCT00871234
Drug Interaction - Oral Contraceptive
Bristol-Myers Squibb
NCT00399685
Using Implementation Science to Increase Pre-Exposure Prophylaxis Uptake Among African American Women
Johns Hopkins Bloomberg School of Public Health
NCT05139069
Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02852005
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine
Merck Sharp & Dohme
NCT00000628
A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000849
A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma
Ligand Pharmaceuticals
NCT00002212
ADAPT-POL New Orleans: Adaptation of Prevention Techniques With Popular Opinion Leader
Centers for Disease Control and Prevention
NCT00252109
Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program
University of Miami
NCT04650269
Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000985
A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000878
A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir
GlaxoSmithKline
NCT03234036
Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00006617
Contingency Management for Cannabis Use for Persons With HIV
The University of Texas Health Science Center at San Antonio
NCT04866004
Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000693
Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance
University of California, San Francisco
NCT00187551
Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
Bristol-Myers Squibb
NCT00135434
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
Gilead Sciences
NCT00002234
A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000956
Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00183261
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Northwestern University
NCT00993148
The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
Boehringer Ingelheim
NCT00002381
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies
Pharmacia and Upjohn
NCT00002210
Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03934541
A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000788
A Study of Stem Cells and Filgrastim
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001071
Development of a New HIV Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00051922
A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761
ViiV Healthcare
NCT01031472
A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex
Amgen
NCT00002281
A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine
Hoffmann-La Roche
NCT00002096
A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000944
Treatment of Hepatitis C in Hemophilic Patients With HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00055341
DDI HV (ATV - Merck)
Bristol-Myers Squibb
NCT00518297
Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00540605
Central Nervous System Disease in HIV-infected Children on HAART
National Cancer Institute (NCI)
NCT00110331
Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
Bristol-Myers Squibb
NCT00162097
Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.
ViiV Healthcare
NCT02206711
Treatment of Acute Hepatitis C Virus in HIV Co-Infection
University of California, San Francisco
NCT00845676
Zidovudine and Lamivudine Given Once Versus Twice Daily
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00014014
Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome
Washington University School of Medicine
NCT00857298
A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines
National Cancer Institute (NCI)
NCT00001571
Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)
Marcus Altfeld, M.D., Ph.D.
NCT00117429
The Effects of Zidovudine on the Blood of HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000965
Antihyperlipidemic Effects of Oyster Mushrooms
National Center for Complementary and Integrative Health (NCCIH)
NCT00069524
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
The Miriam Hospital
NCT00887653
The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients
Gilead Sciences
NCT00002326
Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00105417
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 157 |
| Phase 2 | 109 |
| Phase 3 | 69 |
| Phase 4 | 23 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV Infections trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV Infections page
615 registered trials, 56 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 56 HIV Infections trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most HIV Infections trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV Infections condition card totals 615 registered trials; most-linked intervention Zidovudine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.